InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Primocin® | Directed Differentiation of Murine and Human Small Intestinal Organoids Towar... | 2023 | Methods Mol Biol. | Martinez-Silgado A. et al. | DOI: 10.1007/978-1-0716-3076-1_9 |
| Plasmocin® - Mycoplasma Elimination Reagent | The pro-inflammatory signature of lipopolysaccharide in spontaneous contracti... | 2023 | J Cell Mol Med. | Scharmacher J. et al. | DOI: 10.1111/jcmm.17805 |
| Plasmocin® - Mycoplasma Elimination Reagent | The oncogenic function of PLAGL2 is mediated via ASCL2 and IGF2 and a Wnt-ind... | 2023 | Am J Physiol Gastrointest Liver Physiol. | Fischer A.D. et al. | DOI: 10.1152/ajpgi.00058.2022 |
| QUANTI-Blue™ | Binding, Neutralization and Internalization of the Interleukin-13 Antibody, L... | 2023 | Dermatol Ther (Heidelb) | Okragly A.J. et al. | DOI: 10.1007/s13555-023-00947-7 |
| IL-4 & IL-13 Reporter HEK 293 Cells | Binding, Neutralization and Internalization of the Interleukin-13 Antibody, L... | 2023 | Dermatol Ther (Heidelb) | Okragly A.J. et al. | DOI: 10.1007/s13555-023-00947-7 |
| Anti-murine TLR2 (clone T2.5) Detection and Neutralizing mAb | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
| ODN 1826 - TLR9 ligand | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
| ODN 2088 | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
| LTA-SA | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
| Primocin® | Protocol for generating airway organoids from 2D air liquid interface-differe... | 2023 | STAR Protoc. | Rodenburg L.W. et al. | DOI: 10.1016/j.xpro.2023.102337 |
| CL429 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
| CL401 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
| CL413 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
| LPS-EB (LPS from E. coli O111:B4) | DNA methylation and gene expression changes in mouse mammary tissue during su... | 2023 | Epigenetics | Ivanova E. et al. | DOI: 10.1080/15592294.2023.2215633 |
| Zeocin® | Central repeat fragment of reelin leads to active reelin intracellular signal... | 2023 | Cell Signal | Li Q. et al. | DOI: 10.1016/j.cellsig.2023.110763 |
| MPLA Synthetic | Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aq... | 2023 | Langmuir | Castelletto V. et al. | DOI: 10.1021/acs.langmuir.3c00828 |
| FLA-PA Ultrapure | Bronchial epithelial cells release inflammatory markers linked to airway infl... | 2023 | World Allergy Organ J. | Losol P. et al. | DOI: 10.1016/j.waojou.2023.100786 |
| Zeocin® | Expression of Human β-defensin 2 (hBD-2) in Pichia Pastoris and Investigation... | 2023 | Protein J. | Çobanoğlu Ş. et al. | DOI: 10.1007/s10930-023-10130-8 |
| Normocin® - Antimicrobial Reagent | PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-... | 2023 | J Mammary Gland Biol Neoplasia | Amante R.J. et al. | DOI: 10.1007/s10911-023-09539-9 |
| RAW-Blue™ Cells | The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination I... | 2023 | Mol Pharm. | Jung E. et al. | DOI: 10.1021/acs.molpharmaceut.3c00214 |